Brokers Issue Forecasts for Praxis Precision Medicines, Inc.'s Q1 2025 Earnings (NASDAQ:PRAX)

Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) - Analysts at HC Wainwright issued their Q1 2025 EPS estimates for Praxis Precision Medicines in a research note issued to investors on Tuesday, May 14th. HC Wainwright analyst D. Tsao anticipates that the company will earn ($1.89) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $105.00 target price on the stock. The consensus estimate for Praxis Precision Medicines' current full-year earnings is ($8.64) per share. HC Wainwright also issued estimates for Praxis Precision Medicines' Q2 2025 earnings at ($2.40) EPS.

PRAX has been the subject of a number of other reports. Robert W. Baird initiated coverage on shares of Praxis Precision Medicines in a report on Wednesday, May 1st. They set an "outperform" rating and a $117.00 price target for the company. Jefferies Financial Group raised their price target on shares of Praxis Precision Medicines from $75.00 to $128.00 and gave the stock a "buy" rating in a research report on Tuesday, March 26th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $105.80.

Praxis Precision Medicines Price Performance

PRAX traded down $1.90 during trading hours on Wednesday, reaching $44.00. 702,980 shares of the stock traded hands, compared to its average volume of 222,169. The firm's fifty day simple moving average is $53.35 and its two-hundred day simple moving average is $37.57. The company has a market cap of $752.84 million, a price-to-earnings ratio of -2.89 and a beta of 2.87. Praxis Precision Medicines has a fifty-two week low of $12.45 and a fifty-two week high of $67.21.

Praxis Precision Medicines (NASDAQ:PRAX - Get Free Report) last released its quarterly earnings data on Tuesday, March 5th. The company reported ($2.97) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.05) by $0.08. The company had revenue of $0.52 million during the quarter, compared to analyst estimates of $0.30 million. Praxis Precision Medicines had a negative net margin of 5,711.85% and a negative return on equity of 143.53%.

Institutional Trading of Praxis Precision Medicines

Institutional investors have recently made changes to their positions in the stock. Citigroup Inc. lifted its stake in shares of Praxis Precision Medicines by 44,585.5% in the 3rd quarter. Citigroup Inc. now owns 83,115 shares of the company's stock worth $142,000 after acquiring an additional 82,929 shares during the period. Acuta Capital Partners LLC raised its holdings in shares of Praxis Precision Medicines by 5.5% in the 3rd quarter. Acuta Capital Partners LLC now owns 4,485,000 shares of the company's stock worth $7,669,000 after purchasing an additional 235,000 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of Praxis Precision Medicines by 45.0% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 56,130 shares of the company's stock worth $96,000 after purchasing an additional 17,428 shares in the last quarter. Adage Capital Partners GP L.L.C. raised its holdings in shares of Praxis Precision Medicines by 10.7% in the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 8,780,000 shares of the company's stock worth $15,014,000 after purchasing an additional 849,362 shares in the last quarter. Finally, DLD Asset Management LP bought a new stake in shares of Praxis Precision Medicines in the 4th quarter worth approximately $223,000. 67.84% of the stock is owned by institutional investors and hedge funds.

Praxis Precision Medicines Company Profile

Praxis Precision Medicines, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy.